A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA

NCT02258542 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2133

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

BIOLOGICAL: Benralizumab
BIOLOGICAL: Benralizumab

Sponsor

AstraZeneca